K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · GILD
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $3.2M | Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying the Inflation Reduction Act and other drug pricing |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | MILLER STRATEGIES, LLC | $150K | Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | Issues related to drug pricing |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Issues pertaining to the 340B drug discount program. Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $80K | Prescription drug payment reform. Supply Chain. 340B Program. Implementation of Inflation Reduction Act of 2022. General HIV policy. |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters. |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Issues around drug pricing. |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention. |
| 2026-04-20 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to HIV prevention and procurement. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). |
| 2026-04-18 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |
| 2026-04-18 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. Issues related to HIV medication. |
| 2026-04-09 | GILD | TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. | B HALL STRATEGIES, LLC | $30K | Issues related to drug pricing. |
| 2026-03-09 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2026-01-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | MILLER STRATEGIES, LLC | $150K | Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program. |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $80K | Prescription drug payment reform. Supply Chain. 340B. |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters. |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. |
| 2026-01-20 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. Education about access to HIV medicines. Education about the 340(b) program. |
| 2026-01-19 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to health access. Issues related to HIV medication. |
| 2026-01-19 | GILD | TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. | B HALL STRATEGIES, LLC | $30K | Issues related to HIV medications. Issues related to drug pricing. |
| 2026-01-18 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |
| 2026-01-17 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $60K | Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to HIV prevention and procu |
| 2025-10-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $2.8M | Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | MILLER STRATEGIES, LLC | $150K | Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | HIV Funding Issues related to trade |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program. |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $75K | Issues related to regulation of prescription drugs and biologics |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | Education about access to HIV medicines. Education about the 340(b) program. Implementation H.R.5376 - Inflation Reduction Act of 2022. Public Law 119-21: One Big Beautiful Bill Act. |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model. Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention. |
| 2025-10-20 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $60K | Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). |
| 2025-10-20 | GILD | TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. | B HALL STRATEGIES, LLC | $30K | Monitor issues related to HIV medications. Issues related to drug pricing. Public Law 119-21: One Big Beautiful Bill Act. |
| 2025-10-19 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |
| 2025-10-19 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | PBM reform. PEPFAR funding. |
| 2025-10-17 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters and P.L. 119-21. |
| 2025-10-12 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $80K | Prescription drug payment reform. Supply Chain. 340B. |
| 2025-09-25 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2025-07-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate for provisions modifying |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | MILLER STRATEGIES, LLC | $130K | Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | HIV Funding |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program. |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues IRA, pharmaceuticals access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022. H.R.1 - One Big Beautiful Bill Act. Education about access to HIV medicines Education about the 340(b) program. |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters and H.R. 1, 2025 Budget Reconciliation Bill. |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention. |
| 2025-07-21 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | PBM reform. PEPFAR funding. |
| 2025-07-21 | GILD | TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. | B HALL STRATEGIES, LLC | $30K | Monitor issues related to HIV medications; Issues related to healthcare in the One Big Beautiful Bill Act (PL 119-21). |
| 2025-07-20 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $50K | Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including H.R. 2213/S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to the One Big Beautiful Bill Act (PL 119-21). |
| 2025-07-19 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $80K | Prescription drug payment reform. Supply Chain. 340B. |
| 2025-07-18 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |
| 2025-07-15 | GILD | TIBER CREEK GROUP ON BEHALF OF GILEAD SCIENCES INC. | B HALL STRATEGIES, LLC | $0 | Issues related to drug pricing and reimbursement for prescription drugs; Issues related to Medicare reimbursement and HIV. Issues related to drug pricing and reimbursement for prescription drugs; Issues related to Medicare reimbursement and HIV. |
| 2025-07-14 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2025-05-30 | GILD | GILEAD SCIENCES INC. | MILLER STRATEGIES, LLC | $0 | Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. Issues related to pharmaceuticals and drug development. |
| 2025-04-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. A |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | HIV Funding |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $80K | Prescription drug payment reform. Supply Chain. 340B. |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program. |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters. |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Support for EPIC Act - H.R. 1492 Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. |
| 2025-04-21 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | PBM reform. PEPFAR funding. |
| 2025-04-20 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues IRA, pharmaceuticals access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization Medicare & Medicaid payment and coverage issues |
| 2025-04-20 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $50K | Issues related to international trade; Issues related to intellectual property protections for COVID-19 treatments; Issues related to the TRIPS Waiver; Global supply chain issues, including S. 998 - Medical Supply Chain Resiliency Act; Issues related to compulsory licensing and other intellectual property issues in multiple countries. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158). |
| 2025-04-18 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | Education about access to HIV medicines Education about the 340(b) program. H.R.1492 - EPIC Act. Implementation H.R.5376 - Inflation Reduction Act of 2022. |
| 2025-04-16 | GILD | GILEAD SCIENCES INC. | THEGROUP DC, LLC | $60K | General advocacy surrounding pharmaceuticals and drug development. |
| 2025-04-15 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |
| 2025-04-15 | GILD | GILEAD SCIENCES INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $75K | Issues related to regulation of prescription drugs and biologics |
| 2025-01-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $2.4M | International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. A |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | THE DUBERSTEIN GROUP INC. | $90K | Issues related to cancer moonshot & innovation |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | FARRAGUT PARTNERS LLP | $80K | Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations Issues pertaining to the 340B drug discount program. |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | TARPLIN, DOWNS & YOUNG, LLC | $80K | Federal budget issues IRA implementation, pharmaceutical access and affordability, 340B, HCV screening, drug pricing and access, HIV, oncology, PAPHA reauthorization, transparency Medicare & Medicaid payment and coverage issues |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | THE MCMANUS GROUP | $60K | Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476- Maintaining Investments in New Innovation Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | W STRATEGIES, LLC | $60K | H.R.5378 - Lower Costs, More Transparency Act. Education about the 340(b) program. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform. Implementation H.R.5376 - Inflation Reduction Act of 2022. |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | THEGROUP DC, LLC | $60K | General advocacy surrounding pharmaceuticals and drug development. |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | EMPIRE CONSULTING GROUP | $50K | Issues related to the Continuing Appropriations and Disaster Relief Supplemental Appropriations Act of 2025. |
| 2025-01-21 | GILD | GILEAD SCIENCES INC. | TODD STRATEGY GROUP | $50K | Prescription drug payment reform. Supply Chain. 340B. |
| 2025-01-20 | GILD | GILEAD SCIENCES INC. | CAPITOL TAX PARTNERS, LLP | $60K | Legislative services related to corporate and international tax matters. |
| 2025-01-20 | GILD | GILEAD SCIENCES INC. | TIBER CREEK GROUP | $50K | Issues related to intellectual property protections for COVID-19 vaccines and treatments. Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158). Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158). |
| 2025-01-19 | GILD | GILEAD SCIENCES INC. | FORBES-TATE | $90K | Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening. |